Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + carboplatin + cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer
2022-501139-17-01Phase 2Completed
- Sponsor
- OncoSur
- Start
- Oct 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, carboplatin and cabazitaxel in castration-resistant prostate cancer (CRPC), sponsored by OncoSur. Primary endpoints: Radiographic progression-free survival rate at 6 months and Incidence of adverse events. Started Oct 2022; status: completed.
02
Drugs
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2022-501139-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501139-17-01.